Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Camurus AB ( (SE:CAMX) ) is now available.
Camurus AB has convened its 2026 annual general meeting for 28 May in Lund, Sweden, offering shareholders the option to participate either in person or via postal voting, in line with its articles of association. Shareholders must be registered with Euroclear Sweden by 20 May and complete additional steps, including potential voting rights registration for nominee-held shares, to exercise their votes.
The AGM agenda covers routine corporate governance matters such as adoption of financial statements, dividend decisions, discharge of liability for directors and the CEO, and elections of board members and auditors, along with remuneration approvals. It also includes proposed authorisations for the board to issue new shares and convertibles, manage share buybacks and transfers, and implement a new performance share plan for 2026–2029, measures that may impact capital structure, shareholder returns and management incentives.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK700.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus AB is a Swedish biotechnology company focused on developing and commercialising innovative pharmaceuticals, often using its proprietary drug delivery technologies. The company targets areas with high unmet medical need, particularly in chronic and severe conditions, and its shares are registered with Euroclear Sweden AB.
Average Trading Volume: 134,042
Technical Sentiment Signal: Hold
Current Market Cap: SEK33.62B
For a thorough assessment of CAMX stock, go to TipRanks’ Stock Analysis page.